Sartorius Stedim Biotech Shares Bounce Back 2.5%, Surpassing Moving Averages
The French bioproduction equipment specialist regains momentum at the end of the session, in a notably better-oriented Parisian market. The rebound allows the stock to gain ground above its short-term moving averages, after losing ground the previous day.
A Rebound Above MM20 and MM50 in a Well-Oriented SBF 120
Sartorius Stedim Biotech's stock climbs 2.6% to €177.90 in late afternoon trading, while the SBF 120 increases by 0.67% and the CAC 40 rises by 0.65%. The stock is among the top gainers in the SBF 120, in a Parisian market driven by technology and healthcare stocks. The rebound brings the price above the MM20 (€174.41) and MM50 (€170.78), with respective gaps of +2.00% and +4.17%, extending the momentum established since mid-May.
The MM200, however, remains distant at €185.17, which is 3.93% above the current price, indicating that the medium-term trend remains weak. The RSI at 50 indicates a neutral configuration, without excess in either direction, while the MACD maintains a positive histogram at 0.37, consistent with the day's movement.
Demanding Valuation as Semi-Annual Revenue Approaches
The stock is still down 11.67% year-on-year and continues to trade below its identified resistance at €183.70, a threshold closely watched during previous rebound attempts. Based on expected earnings, the stock is trading at about 35.2 times the earnings for the current fiscal year and 29.6 times those for the next fiscal year, according to the consensus of surveyed analysts, a valuation level that remains demanding for a bioproduction stock. The next concrete milestone remains the resistance at €183.70, whose breach would pave the way for a test of the MM200.
